← Back to home

ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV)

Clinical trials for ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV) explained in plain language.

Never miss a new study

Get alerted when new ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV) trials appear

Sign up with your email to follow new studies for ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First human trial tests new cell therapy for devastating autoimmune diseases

Disease control Recruiting now

This early-stage study is testing the safety of an experimental cell therapy called FT819 for four serious autoimmune diseases: lupus, vasculitis, myositis, and scleroderma. Researchers will give FT819 to 244 participants aged 12-70 who have moderate to severe disease that hasn't…

Matched conditions: ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV)

Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control

Last updated Apr 02, 2026 03:26 UTC

ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV)

Get alerted when new ANTINEUTROPHILIC CYTOPLASMIC ANTIBODY (ANCA)- ASSOCIATED VASCULITIS (AAV) trials appear

First human trial tests new cell therapy for devastating autoimmune diseases